Safari Flower Company, a Wholly Owned Subsidiary of Aurora Cannabis, Receives EU-GMP Certification at Niagara Facility

Safari Flower Company has announced the receipt of European Union Good Manufacturing Practice (EU-GMP) certification for its facility in Ontario, Canada. The certification, valid for three years, enhances Safari's capabilities to operate in international medical cannabis markets subject to stringent regulations.

Brigitte Simons, CEO of Safari Flower Company, expressed pride in achieving the EU-GMP certification, stating that it reinforces the company's reputation as a reliable cultivator and manufacturer of high-quality medical cannabis for global markets. She highlighted the significance of compliance and operational excellence in supporting the company's partnerships within regulated supply chains.

The Ontario facility spans 59,000 square feet and has a history of EU-GMP accreditations and exporting operations. Aurora Cannabis Inc. acquired Safari Flower Company in April 2026 to augment its EU-GMP capacity and strengthen the supply of high-quality medical cannabis to international markets, including Germany, Poland, and the UK.

As international medical cannabis markets continue to evolve, EU-GMP certification is seen as a vital measure enabling Safari to serve regulated markets confidently. The company aims to meet the demands for high-quality medical cannabis that adhere to rigorous quality, safety, and compliance standards.

Safari Flower Company operates as a subsidiary of Aurora Cannabis Inc., dedicated to producing safe medical cannabis products while facilitating Canadian exports to international markets. Aurora is recognized as a global leader in medical cannabis, committed to enhancing patient lives through scientific expertise and quality care.